A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Recruiting · NCT07612176 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 | 2026-09-25 | NCT07612176 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| NEOK Bio, Inc. | 2 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| NEXT Oncology | Dallas | United States | 4 |
| NEXT Oncology | Houston | United States | 5 |
| NEXT Oncology | Fairfax | United States | 31 |
| NEXT Oncology | Austin | United States | 8 |
| NEXT Oncology | San Antonio | United States | 1 |
| SCRI at Mary Crowley | Dallas | United States | 6 |
| Scri Oncology Partners | Nashville | United States | 156 |